Valuation : VolitionRx Limited

Market Cap 4.97M 4.28M 4.02M 3.67M 6.87M 469M 6.89M 47.49M 18.41M 240M 18.64M 18.24M 776M P/E 2026 *
-0.17x
P/E 2027 * -0.35x
Enterprise Value 4.97M 4.28M 4.02M 3.67M 6.87M 469M 6.89M 47.49M 18.41M 240M 18.64M 18.24M 776M EV / Sales 2026 *
1.99x
EV / Sales 2027 * 0.94x
Free-Float
85%
Yield 2026 *
-
Yield 2027 * -
1 day-0.09%
1 week-22.19%
Current month-19.43%
1 month-55.49%
3 months-82.52%
6 months-91.35%
Current year-93.16%
1 week 0.33
Extreme 0.33
0.45
1 month 0.33
Extreme 0.3269
0.81
Current year 0.33
Extreme 0.3269
7.73
1 year 0.33
Extreme 0.3269
14.8
3 years 0.33
Extreme 0.3269
27.6
5 years 0.33
Extreme 0.3269
82.8
10 years 0.33
Extreme 0.3269
136.8
Manager TitleAgeSince
Chief Executive Officer 55 2011-10-05
Director of Finance/CFO 56 2021-01-31
Chief Tech/Sci/R&D Officer 49 2024-03-31
Director TitleAgeSince
Director/Board Member 55 2011-10-05
Director/Board Member 77 2011-10-05
Director/Board Member 64 2019-10-08
Date Insider Type Main position Quantity % Market Cap. Importance
3/17/26
Concord International, Inc.
OtherCompany 0 0% -
3/17/26 Tax

Executive/Senior Manager

5,251 0.0039%
3/17/26 Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%-22.19%-97.25%-98.64% 4.97M
+1.03%+9.74%+299.55%+42.93% 3.98B
-1.18%-3.61%+86.48%+256.53% 3.87B
-4.79%-1.87%+34.93%+59.29% 3.42B
+2.05%+2.19%+288.40%+422.92% 2.63B
-1.65%-6.73%-26.25%-32.04% 2.11B
-3.49%+10.28%+54.60% - 1.75B
-0.68%-4.69%+210.17%-28.93% 1.09B
+1.11%-10.52%+24.12%+41.15% 1.08B
-1.55%-11.92%+9.29%+49.84% 609M
Average -0.92%-2.82%+88.40%+79.23% 2.06B
Weighted average by Cap. -1.05%+0.77%+131.73%+130.65%

Financials

2026 *2027 *
Net sales 2.49M 2.14M 2.01M 1.84M 3.45M 235M 3.46M 23.82M 9.23M 121M 9.35M 9.15M 389M 5.27M 4.54M 4.26M 3.9M 7.29M 498M 7.31M 50.37M 19.53M 255M 19.78M 19.34M 823M
Net income -21.62M -18.62M -17.49M -15.99M -29.92M -2.04B -30.02M -207M -80.18M -1.05B -81.19M -79.42M -3.38B -18.42M -15.86M -14.9M -13.62M -25.49M -1.74B -25.57M -176M -68.3M -892M -69.16M -67.65M -2.88B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
26-09-04 US$0.3496 -0.09% 1,173,742
26-09-03 US$0.3499 -7.04% 2,001,342
26-09-02 US$0.3764 -4.52% 1,917,099
26-09-01 US$0.3942 -9.15% 2,344,492
26-08-31 US$0.4339 -3.43% 5,010,871
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.3496USD
Average target price
16.57USD
Spread / Average Target
+4,638.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock